Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Nick S R Lan"'
Publikováno v:
Journal of Cardiovascular Development and Disease, Vol 11, Iss 9, p 291 (2024)
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia, with catheter ablation being a key alternative to medical treatment for restoring normal sinus rhythm. Despite advances in understanding AF pathogenesis, approximately 35% of pat
Externí odkaz:
https://doaj.org/article/7529444a80254f53a633277eddb7b63b
Autor:
Peter P. Toth, Jean Ferrières, Max Waters, Martin Bødtker Mortensen, Nick S. R. Lan, Nathan D. Wong
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and addition
Externí odkaz:
https://doaj.org/article/addedc3ef14445b8864bc454821eac33
Autor:
Nick S. R. Lan
Publikováno v:
The Anatolian Journal of Cardiology. 27:132-134
Autor:
Nick S. R. Lan, Damon A. Bell, Kieran A. McCaul, Samuel D. Vasikaran, Bu B. Yeap, Paul E. Norman, Osvaldo P. Almeida, Jonathan Golledge, Graeme J. Hankey, Leon Flicker
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 5 (2019)
Background The Framingham Risk Score estimates the 10‐year risk of cardiovascular events. However, it performs poorly in older adults. We evaluated the incremental benefit of adding high‐sensitivity cardiac troponin I (hs‐cTnI) to the Framingha
Externí odkaz:
https://doaj.org/article/05467a34fa994406b688b77e5387d6d5
Autor:
Travis Chong, Nick S. R. Lan, William Courtney, Albert He, Geoff Strange, David Playford, Girish Dwivedi, Graham S. Hillis, Abdul Rahman Ihdayhid
Publikováno v:
Cardiology in Review.
Autor:
Dipen Mayurkumar Sankhesara, Nick S. R. Lan, Poppy Gilfillan, Elly Zounis, Saumya Rajgopal, Dick C. Chan, Jing Pang, Graham S. Hillis, Gerald F. Watts, Carl J. Schultz
Publikováno v:
Cardiology.
Background Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease. The burden of thrombus in ST-segment elevation myocardial infarction (STEMI) has implications on treatment and outcomes. However, the association between Lp(a) and atherot
Publikováno v:
Clinical and experimental nephrology.
Publikováno v:
Coronary Artery Disease. 33:593-595
Autor:
Jenny Nguy, Sarah A. Hitchen, Nick S. R. Lan, Girish Dwivedi, Robert Larbalestier, Bu B. Yeap, P. Gerry Fegan
Publikováno v:
Internal Medicine Journal.
Guidelines advocate for intensive lipid-lowering in patients with atherosclerotic cardiovascular disease (ASCVD). In May 2020, evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, became government subsidised in Australia fo
Publikováno v:
Journal of Medical Imaging and Radiation Oncology. 66:802-804